Preliminära resultat från Fas III-studier av ETEC-vaccinet
March 29, 2000 02:23 ET | Active Biotech
Två Fas III-studier för ETEC-vaccinet mot turistdiarré genomförs i Guatemala och Mexico, båda koordinerade från Johns Hopkins School of Hygiene and Public Health i Baltimore, USA. Den första...
Invitation to Annual Meeting of Shareholders
March 15, 2000 06:30 ET | Active Biotech
The Board of Directors of Active Biotech AB (publ) has today issued a notification of the Annual General Meeting, which is to take place at 17.00 on 12 April 2000 at the Star Hotel in Lund. The...
Kallelse till bolagsstämma
March 15, 2000 05:15 ET | Active Biotech
Active Biotech AB:s (publ) styrelse har idag utfärdat kallelse till årets ordinarie bolagsstämma, vilken kommer äga rum den 12 april 2000 kl.17.00 på Star Hotel i Lund. Kallelsen, som införs idag i...
Patent for SAIK-MS approved in the USA
March 02, 2000 03:25 ET | Active Biotech
Active Biotech has received patent approval for a group of chemical substances containing candidate drugs against autoimmune and inflammatory diseases. The application in the USA was presented in...
Patent för SAIK-MS beviljat i USA
February 29, 2000 10:07 ET | Active Biotech
Active Biotech har fått beviljat ett patent för en kemisk substansgrupp innefattande läkemedelskandidater mot autoimmuna och inflammatoriska sjukdomar. Ansökan inlämnades i USA i april 1999 och patent...
Active Biotech Group Annual Accounts Report January - December 1999
February 21, 2000 09:08 ET | Active Biotech
ACTIVE BIOTECH INVESTS IN NEW PHARMACEUTICALS AGAINST CANCER Active Biotech acquires TTS Active Biotech and Pharmacia & Upjohn, P&U, have signed a Letter of Intent concerning to the "TTS"; Tumor...
Bokslutskommuniké januari - december 1999
February 18, 2000 02:56 ET | Active Biotech
ACTIVE BIOTECH SATSAR PÅ NYA LÄKEMEDEL MOT CANCER Active Biotech förvärvar TTS Active Biotech och Pharmacia & Upjohn, P&U, har tecknat ett Letter of Intent avseende forskningsområdet ”TTS”; Tumor...
The Swedish Medical Products Agency has approved for Active Biotech to expand Phase I-trials and include patients with multiple sclerosis
February 11, 2000 09:41 ET | Active Biotech
During the autumn 1999, SAIK-MS, a substance intended for use in patients with multiple sclerosis, has been tested on healthy volunteers with very promising results. The Swedish medical products...
Läkemedelsverket har godkänt att Active Biotech genomför en utvidgad Fas I-prövning som även inkluderar patienter med sjukdomen multipel skleros
February 11, 2000 05:33 ET | Active Biotech
Under hösten 1999 har SAIK-MS, en substans avsedd för multipel skleros, testats på friska personer med mycket lovande resultat. Läkemedelsverket har nu godkänt en mer omfattande studie med fler...
New production manager for Active Biotech
January 10, 2000 09:15 ET | Active Biotech
Börje Haag has been appointed production manager at Active Biotech AB and will be taking up his position in February being based at SBL Vaccin in Solna, Sweden. He is presently Vice President,...